The data and safety monitoring board for a phase 1/2 study clinical trial of a geographic atrophy gene therapy approved continuation of the second phase of the study due to positive safety results, according to a press release from Ocugen.
The ArMaDa study is investigating the unilateral subretinal administration of OCU410 for geographic atrophy secondary to dry age-related macular degeneration. The ongoing, randomized, outcome assessor-blinded, dose-expansion phase 2 study randomly assigned 45 patients to either one of two OCU410 treatment groups (5×1010 vg/mL or 1.5 ×1011 vg/mL)